Amgen Inc. or GSK plc: Who Leads in Yearly Revenue?

Amgen Inc. vs. GSK plc: A Revenue Showdown

In the competitive landscape of the pharmaceutical industry, Amgen Inc. and GSK plc have been formidable players. Over the past decade, GSK has consistently outpaced Amgen in annual revenue, with GSK's earnings peaking at approximately $34 billion in 2021, a 20% increase from 2014. Meanwhile, Amgen's revenue has shown a steady climb, reaching around $28 billion in 2023, marking a 40% growth since 2014.

Despite GSK's lead, Amgen's growth trajectory is noteworthy, especially in recent years. From 2020 to 2023, Amgen's revenue surged by nearly 11%, while GSK's revenue saw a slight dip of 11% in 2022 before rebounding in 2023. This dynamic shift highlights the evolving strategies and market conditions influencing these pharmaceutical giants. As the industry continues to innovate, the revenue race between Amgen and GSK remains a captivating narrative for investors and analysts alike.